Levi & Korsinsky is investigating the Board of Directors of inVentiv Health, Inc. (“inVentiv Health” or the “Company”) (NasdaqGS: VTIV) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to private equity firm Thomas H. Lee Partners, L.P. ("THL"). Under the terms of the transaction, inVentiv Health shareholders will receive $26.00 in cash for each inVentiv Health share of common stock they own for a total transaction value of approximately $1.1 billion. For the quarter ending December 31, 2009, inVentiv Health reported total revenue of $274.803 million and net income of $15.947 million as compared to total revenue and net income of $270.465 million and $11.723 million, respectively, for the prior quarter. The investigation concerns whether the inVentiv Health Board of Directors breached their fiduciary duties to inVentiv Health stockholders by failing to adequately shop the Company before entering into this transaction and whether THL is underpaying for inVentiv Health shares, thus unlawfully harming inVentiv Health stockholders. At least one analyst set a price target for inVentiv Health stock at $27.00 per share. If you own common stock in inVentiv Health and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500 or visit http://www.zlk.com/inventiv-health-vtiv.html. Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation.